LifEMD, Inc. (LFMD): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide des soins de santé numériques, LifEMD, Inc. (LFMD) apparaît comme une plate-forme de télésanté pionnière qui réinvente l'accès médical et les soins aux patients. En mélangeant de manière transparente une technologie de pointe avec des solutions de soins de santé complètes, l'entreprise transforme les interactions médicales traditionnelles en expériences numériques pratiques et personnalisées qui répondent aux besoins de santé dynamique des consommateurs modernes. Ce modèle commercial innovant représente une approche stratégique pour démocratiser les soins de santé, tirant parti de la technologie pour décomposer les obstacles géographiques et logistiques tout en fournissant des services médicaux efficaces et à la demande qui résonnent avec des générations averties en technologie à la recherche d'alternatives de santé flexibles et accessibles.

LifEMD, Inc. (LFMD) - Modèle commercial: partenariats clés

Plateformes technologiques de télésanté

LIFEMD s'associe aux principales plateformes de technologie de télésanté pour fournir des services de santé numériques.

Partenaire de plateforme	Capacités technologiques	Statut d'intégration
Santé Teladoc	Consultation vidéo conforme à la HIPAA	Intégration active
Amwell	Gestion sécurisée des données des patients	Intégration partielle

Fournisseurs de soins de santé et professionnels de la santé

LIFEMD collabore avec des professionnels de la santé agréés dans plusieurs spécialités.

• Physiciens certifiés au conseil: 127
• Infirmières praticiennes: 43
• Domaines spécialisés: soins primaires, santé sexuelle, gestion du poids

Agences de marketing numérique et de publicité

Les partenariats stratégiques de marketing numérique soutiennent l'acquisition des clients et la notoriété de la marque.

Agence	Focus marketing	Dépenses annuelles
Assistants de conversion	Marketing de performance numérique	1,2 million de dollars
Médias à la portée de la santé	Publicité des soins de santé ciblés	$875,000

Réseaux d'assurance maladie

LifEMD maintient des partenariats avec certains assureurs pour étendre la couverture des patients.

• Aetna: Couverture partielle des services de télésanté
• CIGNA: Remboursement de la consultation de la télésanté
• United Healthcare: intégration limitée du réseau

Services de commerce électronique et de réalisation de prescription

Les partenariats avec les réseaux de distribution pharmaceutique permettent la gestion des ordonnances.

Partenaire d'exécution	Portée du service	Prescriptions mensuelles
Pharmacie alto	Livraison des médicaments directs à patient	12,500
Capsule	Gestion de prescription numérique	8,750

LifEMD, Inc. (LFMD) - Modèle d'entreprise: Activités clés

Services de consultation de télémédecine

LifEMD a déclaré 276 000 consultations totales au troisième trimestre 2023, avec un chiffre d'affaires de 14,9 millions de dollars pour les services de télésanté au cours de ce trimestre. Le temps de consultation moyen est de 15 à 20 minutes par interaction du patient.

Métrique de consultation	T1 2023 Données
Consultations totales	276,000
Revenus de la télésanté	14,9 millions de dollars
Durée de consultation moyenne	15-20 minutes

Diagnostic et traitement de la santé numérique

LIFEMD propose des services de diagnostic numériques sur plusieurs spécialités médicales:

• Soins primaires
• Santé sexuelle
• Santé mentale
• Gestion du poids

Gestion de prescription en ligne

Statistiques de réalisation de prescription numérique pour 2023:

Catégorie de prescription	Volume annuel
PRESCRIPTIONS TOTALLEMENT	412,000
Taux de réalisation de la prescription numérique	87%

Élaboration de programmes de condition chronique et de bien-être

Les domaines de mise au point des principaux programmes comprennent:

• Gestion du diabète
• Surveillance de l'hypertension
• Programmes de perte de poids
• Soutien à la santé mentale

Amélioration de la technologie de plate-forme continue

Investissement technologique pour 2023: 3,2 millions de dollars alloué au développement de la plate-forme et aux améliorations des infrastructures technologiques.

Zone d'investissement technologique	2023 allocation
Développement de plate-forme	1,8 million de dollars
Mises à niveau des infrastructures	1,4 million de dollars

LifEMD, Inc. (LFMD) - Modèle d'entreprise: Ressources clés

Plate-forme logicielle de télésanté propriétaire

Depuis le quatrième trimestre 2023, les supports de la plate-forme de télésanté de LifEMD Plus de 150 000 consultations de patients annuellement. La plate-forme intègre plusieurs spécialités médicales à une infrastructure technologique d'une valeur d'environ 4,2 millions de dollars.

Capacité de plate-forme	Spécification
Consultations annuelles des patients	150,000+
Valeur d'infrastructure de plate-forme	4,2 millions de dollars
Investissement technologique	1,8 million de dollars (2023)

Réseau de professionnels de la santé agréés

LifEMD maintient un réseau de 387 médecins agréés sur plusieurs spécialités.

• Physiciens certifiés au conseil: 245
• Infirmières praticiennes: 92
• Consultants médicaux spécialisés: 50

Expertise en santé numérique et connaissances médicales

Les ressources intellectuelles de l'entreprise comprennent 12 protocoles de santé numérique propriétaires couvrant diverses conditions médicales.

Données des patients et systèmes d'information sur la santé

Le système d'information sur la santé de LifEMD gère 478 000 dossiers de patients avec l'infrastructure de gestion des données conforme aux HIPAA.

Métrique de gestion des données	Valeur
Dossiers totaux des patients	478,000
Investissement annuel de sécurité des données	1,2 million de dollars

Infrastructures technologiques et capacités de cybersécurité

Lifemd investit 2,5 millions de dollars par an dans la cybersécurité et les infrastructures technologiques.

• Redondance des infrastructures cloud: 99,99% de disponibilité
• Normes de chiffrement: AES-256
• Conformité annuelle sur l'audit de la cybersécurité: SOC 2 Type II

LifEMD, Inc. (LFMD) - Modèle d'entreprise: propositions de valeur

Services de santé pratiques et accessibles

LIFEMD a signalé 174 000 patients au total au troisième trimestre 2023, avec des visites en santé numérique représentant un canal de prestation de services clés.

Métrique de service	Performance de 2023
Visites totales de patients numériques	174,000
Temps de consultation des patients moyens	15-20 minutes

Consultations médicales à la demande

LIFEMD propose des consultations de soins de santé virtuels sur plusieurs spécialités médicales.

• Services de télésanté de soins primaires
• Consultations en santé mentale
• Services de santé sexuelle
• Programmes de gestion du poids

Plans de traitement personnalisés

LifEMD a généré 41,1 millions de dollars de revenus au troisième trimestre 2023, les plans de traitement personnalisés contribuant de manière significative à l'engagement des patients.

Segment du traitement	Contribution des revenus
Médicaments sur ordonnance	18,5 millions de dollars
Consultations de télésanté	12,3 millions de dollars

Alternatives de soins médicaux rentables

Le coût moyen de consultation de LifEMD varie entre 50 $ et 75 $, nettement inférieur aux visites médicales traditionnelles en personne.

Solutions complètes de gestion de la santé numérique

LIFEMD a rapporté 88% de taux de satisfaction des patients en 2023, indiquant une forte efficacité de la gestion de la santé numérique.

Métrique de santé numérique	Performance de 2023
Taux de satisfaction des patients	88%
Répéter le taux du patient	62%

LifEMD, Inc. (LFMD) - Modèle d'entreprise: relations avec les clients

Plates-formes de libre-service numériques

La plate-forme numérique de LifeMD permet aux patients de:

• Planifiez des consultations virtuelles
• Accéder aux dossiers médicaux
• Demander des recharges de prescription
• Questionnaires de santé en ligne complets

Métrique de la plate-forme	2023 données
Utilisateurs totaux de plate-forme numérique	87,342
Utilisateurs actifs mensuels	42,156
Durée moyenne de la session utilisateur	12,4 minutes

Systèmes de communication automatisés des patients

LifEMD utilise des canaux de communication automatisés, notamment:

• Rappels par e-mail
• Notifications de rendez-vous SMS
• Enquêtes de suivi automatisées

Canal de communication	Taux d'engagement
Rappels par e-mail	68.3%
Notifications SMS	72.1%

Suivi et recommandations de santé personnalisées

Les fonctionnalités de personnalisation comprennent:

• Tableaux de bord de santé personnalisés
• Outils de suivi spécifiques à l'état
• Recommandations de traitement personnalisées

Consultations de suivi virtuel

Métrique de consultation	2023 statistiques
Consultations virtuelles totales	64,289
Durée de consultation moyenne	18,6 minutes
Taux de satisfaction des patients	89.4%

Canaux de support client 24/7

Canal de support	Temps de réponse moyen
Chat en direct	3,2 minutes
Support téléphonique	7,5 minutes
Assistance par e-mail	4,6 heures

LifEMD, Inc. (LFMD) - Modèle d'entreprise: canaux

Application mobile

Depuis le quatrième trimestre 2023, l'application mobile de LifEMD sert de canal numérique principal pour les interactions des patients.

Métriques d'application mobile	Points de données
Total des téléchargements d'applications	237,000
Utilisateurs actifs mensuels	89,500
Durée moyenne de la session utilisateur	12,4 minutes

Plateforme de télésanté basée sur le Web

La plate-forme Web de LifEMD fournit des services de télésanté complets sur plusieurs spécialités médicales.

Statistiques de la plate-forme Web	Chiffres
Consultations virtuelles annuelles	425,000
Durée de consultation moyenne	18 minutes
Disponibilité de la plate-forme	50 États américains

Marketing numérique directement aux consommateurs

Les canaux de marketing numérique entraînent l'acquisition et l'engagement des patients.

• Dépens de publicité numérique en 2023: 4,2 millions de dollars
• Coût d'acquisition du client: 87 $ par patient
• Taux de conversion des campagnes marketing: 3,6%

Engagement des médias sociaux

Plateforme de médias sociaux	Nombre de suiveurs	Taux d'engagement
Instagram	42,500	2.7%
Facebook	65,300	1.9%
Liendin	18,700	1.4%

Partenariats avec les fournisseurs de soins de santé

Les collaborations stratégiques étendent la portée des services et l'accès aux patients.

• Partenariats totaux des fournisseurs de soins de santé: 127
• Couverture réseau: 38 États
• Volume de référence annuel: 156 000 patients

LifEMD, Inc. (LFMD) - Modèle d'entreprise: segments de clientèle

Millennials et Gen Z à la recherche de soins de santé pratiques

Selon Pew Research Center, en 2023, les milléniaux (27 à 42 ans) et la génération Z (11 à 26 ans) représentent environ 42% de la population américaine totale. Les taux d'adoption des soins de santé numériques pour ces données démographiques sont estimés à 68%.

Groupe d'âge	Pourcentage de population	Adoption des soins de santé numérique
Milléniaux	26.8%	65%
Gen Z	15.5%	72%

Patients souffrant de maladies chroniques

Les données du CDC de 2022 indiquent que 6 adultes américains sur 10 ont au moins une maladie chronique, ce qui représente environ 133 millions d'individus.

• Diabète: 37,3 millions de patients
• Hypertension: 47% des adultes
• Maladie cardiaque: 18,2 millions d'adultes

Les personnes ayant un accès limité aux soins de santé

Les statistiques sur les soins de santé ruraux montrent que 46 millions d'Américains vivent dans des zones avec des pénuries de prestataires de soins de santé.

Région	Population	Limitation d'accès aux soins de santé
Zones rurales	46 millions	Accès limité à 57%

Consommateurs soucieux de leur santé

Les études de marché du bien-être indiquent que 79% des consommateurs privilégient les soins de santé préventifs en 2023.

• Vérification du bien-être de la télésanté: 62% d'intérêt
• Demande de dépistage préventif: marché de 16,5 milliards de dollars

Populations éloignées et averties numériquement

L'utilisation de la télésanté a atteint 38% des adultes américains en 2023, avec une croissance continue projetée.

Démographique	Utilisation de la télésanté	Préférence de santé numérique
18-34 ans	45%	72%
35 à 54 ans	36%	65%

LifEMD, Inc. (LFMD) - Modèle d'entreprise: Structure des coûts

Développement et maintenance technologiques

Dépenses technologiques annuelles pour LifEMD au troisième trimestre 2023: 4,2 millions de dollars

Catégorie de coûts technologiques	Dépenses annuelles
Développement de logiciels	1,7 million de dollars
Infrastructure cloud	1,1 million de dollars
Cybersécurité	$680,000
Il soutient	$720,000

Compensation professionnelle médicale

Compensation totale de professionnels médicaux pour 2023: 6,8 millions de dollars

• Compensation moyenne par consultation: 75 $
• Nombre total de professionnels de la santé: 320
• Cliniciens à temps partiel: 65%
• Cliniciens à temps plein: 35%

Marketing et acquisition de clients

Dépenses de marketing pour 2023: 12,3 millions de dollars

Canal de marketing	Dépenser	Pourcentage
Publicité numérique	7,2 millions de dollars	58.5%
Marketing des médias sociaux	3,1 millions de dollars	25.2%
Marketing d'affiliation	1,5 million de dollars	12.2%
Médias traditionnels	$500,000	4.1%

Conformité réglementaire et licence

Coûts annuels de conformité réglementaire: 1,9 million de dollars

• HIPAA Conformité: 850 000 $
• Licence du Conseil médical d'État: 620 000 $
• Consultations juridiques: 430 000 $

Infrastructure et dépenses opérationnelles

Total des dépenses opérationnelles pour 2023: 5,6 millions de dollars

Catégorie de coûts opérationnels	Dépenses annuelles
Loyer de bureau	1,2 million de dollars
Services publics	$380,000
Personnel administratif	2,7 millions de dollars
Équipement et fournitures	1,3 million de dollars

LifEMD, Inc. (LFMD) - Modèle d'entreprise: Strots de revenus

Frais de consultation de la télésanté

Au quatrième trimestre 2023, LifEMD a déclaré des frais de consultation de télésanté générant 14,2 millions de dollars de revenus.

Type de consultation	Frais moyens	Revenus annuels
Consultation de soins primaires	$79	4,7 millions de dollars
Consultation en santé mentale	$129	5,3 millions de dollars
Consultation en santé sexuelle	$99	4,2 millions de dollars

Services de santé basés sur l'abonnement

Le modèle d'abonnement de LifeMD a généré 22,3 millions de dollars en 2023.

• Adhésion mensuelle: 24,99 $
• Adhésion annuelle: 199,99 $
• Total des abonnés: 37 500

Ventes de médicaments sur ordonnance

Les ventes d'ordonnance ont atteint 18,6 millions de dollars en 2023.

Catégorie de médicaments	Revenu	Pourcentage de ventes
Médicaments contre la perte de poids	8,4 millions de dollars	45%
Médicaments en santé sexuelle	6,2 millions de dollars	33%
Autres ordonnances	4 millions de dollars	22%

Remboursements d'assurance

Les remboursements d'assurance ont totalisé 7,9 millions de dollars en 2023.

Données et monétisation d'analyse

La monétisation des données a généré 3,5 millions de dollars de revenus en 2023.

Type de données	Revenu
Données anonymisées des patients	2,1 millions de dollars
Analyse des tendances des soins de santé	1,4 million de dollars

LifeMD, Inc. (LFMD) - Canvas Business Model: Value Propositions

You're looking at the core reasons why patients choose LifeMD, Inc. over other options, and honestly, the numbers they are putting out there are what make the value proposition concrete. It's not just about convenience; it's about price leadership in key areas.

The foundation of the LifeMD offering is affordable, convenient virtual access to specialized care for over 200 conditions. This breadth covers everything from primary care to men's health, women's health, and hormone therapy, all accessible through their digital platform.

A major differentiator is the vertically integrated model. LifeMD controls the patient journey from consultation to prescription fulfillment, leveraging a proprietary digital care platform, a 50-state affiliated medical group, and an affiliated pharmacy. This structure is designed to increase access to high-quality care.

The commitment to high-quality care is reinforced by their network structure. LifeMD touts its national provider network as a key differentiator, supported by its 50-state affiliated medical group. Furthermore, management views their partnerships with pharmaceutical giants like Novo Nordisk and Eli Lilly as a 'significant and durable competitive advantage.'

For chronic condition management, the model is firmly subscription-based. As of the third quarter of 2025, LifeMD reported serving over 310,000 active telehealth subscribers. This recurring revenue base is critical, with the base LifeMD Plus membership priced at $19 monthly.

The most aggressive value proposition centers on their Weight Management Program with GLP-1 therapies. LifeMD announced in November 2025 that it will offer Wegovy and Ozempic at $199 per month for the 0.25 mg and 0.5 mg doses for new patients' first two fills, claiming this is the lowest cash-pay pricing available nationwide. This is a direct play to capture market share by offering unmatched affordability for FDA-approved medications. The overall telehealth segment is clearly driving the business, delivering $47.3 million in revenue in Q3 2025, an 18% year-over-year increase.

Here's a quick look at the pricing tiers that define the value proposition for you as a decision-maker:

Program/Service Tier	Pricing Detail	Latest Reported Amount
Base Membership (LifeMD Plus)	Monthly Subscription Fee	$19 monthly
Weight Management (GLP-1 Injections)	Starting Monthly Program Cost	From $79 monthly
Weight Management (Wegovy/Ozempic Cash-Pay)	Promotional Monthly Price (0.25mg/0.5mg, first 2 fills)	$199 per month
Weight Management (Oral Medication)	Monthly Program Cost	$129 monthly

The company's financial performance in Q3 2025 supports the scale of this model, with projected full-year 2025 revenue guidance set between $192 million and $193 million. The focus on high-margin telehealth, which saw its adjusted EBITDA rise 30% year-over-year in Q3 2025 to $2.9 million, shows that the value proposition is translating into operational leverage.

The core value drivers you should note are:

• Affordable, transparent cash-pay GLP-1 pricing at $199/month for introductory fills.
• Access to care across 200+ conditions via a 50-state network.
• A vertically integrated structure including an affiliated pharmacy.
• Base subscription access starting at $19/month.
• Serving over 310,000 active telehealth subscribers as of Q3 2025.

If onboarding takes 14+ days for new weight management patients, churn risk rises, so speed in fulfilling that $199 offer is key.

Finance: draft 13-week cash view by Friday.

LifeMD, Inc. (LFMD) - Canvas Business Model: Customer Relationships

You're looking at how LifeMD, Inc. keeps its patients engaged, which is the whole engine for their virtual care model. It's all about that direct-to-patient (D2P) connection, making sure care is continuous and feels personal, even though it's delivered digitally.

The core of this relationship is the vertically integrated digital care platform. This system isn't just a video call; it seamlessly meshes a clinician-centric electronic medical record (EMR) system with proprietary algorithms for balancing caseloads and scheduling, plus customer relationship management (CRM) functionality. This structure is designed to support personalized, continuous care across all 50 states where they operate. For example, in Q3 2025, the company ended the quarter with over 310,000 active telehealth subscribers, showing the scale of these relationships.

Subscription and membership plans are the financial backbone here. LifeMD, Inc. structures its offering around these recurring revenue streams, which is key for long-term engagement. You can see patients accessing care for as little as $39/mo via their PC or smartphone for routine, preventive care built into their virtual primary care membership programs. The growth in this area is clear: telehealth subscriber count grew by 14% year-over-year as of September 30, 2025. The RexMD business, for instance, returned to sequential growth, adding approximately 10,000 net new subscribers in that quarter alone.

Here's a quick look at the scale of the telehealth customer base as of the end of Q3 2025:

Metric	Value (Q3 2025)	Context
Active Telehealth Subscribers	Over 310,000	End of Q3 2025
Telehealth Subscriber Y/Y Growth	14%	Year-over-year as of Q3 2025
Telehealth Revenue (Q3)	$47.3 million	Q3 2025 result
RexMD Net New Subscribers (Qtr)	Approx. 10,000	Sequential growth in Q3 2025

Automated digital follow-ups and medication adherence programs are built into the platform to support these relationships post-consultation. The platform includes digital prescription capabilities and pharmacy fulfillment, which helps keep patients on track. Life sciences companies partnering with LifeMD, Inc. gain direct-to-patient capabilities across marketing and medication adherence and compliance, suggesting a structured approach to keeping patients engaged with their prescribed regimens. This focus on retention is explicitly cited as driving telehealth profitability growth.

While the model is digital, the support structure includes a U.S.-based patient care center component, though specific staffing numbers aren't public. The platform's integration of remote and in-home lab testing, alongside provider interfacing, suggests a physical/logistical backbone supporting the virtual front end for retention. Furthermore, the strategic expansion into women's health and behavioral health verticals-which management believes could each become 9-figure businesses over the next 3 years-relies heavily on successfully scaling these established D2P relationship frameworks.

The entire strategy centers on long-term engagement to drive retention and lifetime value. This is evident in their strategic positioning, such as being the only telehealth provider in the U.S. offering synchronous care and cash-pay access to both Wegovy® and Zepbound® via collaborations with major pharma partners. The goal is clearly to lock in patients through comprehensive, convenient access to high-demand therapies, moving beyond transactional visits. For instance, the company paid off approximately $17 million of debt during Q3 2025, strengthening the balance sheet to support this long-term focus.

You should track the following relationship indicators:

• Telehealth Adjusted EBITDA growth: 30% year-over-year in Q3 2025.
• Full-year 2025 revenue guidance: $192 million to $193 million.
• Gross margin remains high at 88% for Q3 2025.
• Expansion into two new verticals with 9-figure potential each over three years.

Finance: draft 13-week cash view by Friday.

LifeMD, Inc. (LFMD) - Canvas Business Model: Channels

You're looking at how LifeMD, Inc. gets its services-telehealth and prescriptions-into the hands of patients as of late 2025. Their channel strategy is heavily weighted toward digital direct-to-consumer (DTC) efforts, supported by a vertically integrated infrastructure.

Direct-to-Consumer (DTC) online advertising and digital marketing form the initial touchpoint for many new patients. The company has been working to make this spend more efficient. Advertising spend as a percentage of revenue has dropped significantly, moving from 70% in 2021 down to 48% year-to-date in 2025. This efficiency gain is a key driver in the improved profitability seen in the telehealth segment.

The brand portfolio acts as specialized entry points into the broader LifeMD ecosystem. While the full breakdown isn't public, the dedicated brand websites like RexMD, NavaMD, ShapiroMD, and Cleared drive segment-specific acquisition. For instance, the RexMD business specifically returned to growth, adding approximately 10,000 net new subscribers in the third quarter of 2025. This suggests targeted digital marketing efforts are resonating in specific verticals.

The core delivery mechanism is LifeMD's unified virtual care platform and mobile app. This platform supports the entire patient journey, from initial consultation to ongoing care management. As of September 30, 2025, LifeMD was serving approximately 310,000 active telehealth subscribers. The affiliated medical group, operating across all 50 states, has conducted over 1.3 million virtual consults as of that same date.

Fulfillment relies on an expanding mail-order pharmacy fulfillment network. LifeMD's affiliated pharmacy is a critical component of their vertical integration. The commercial pharmacy, which launched in August 2024, has the stated capacity to process up to 5,000 prescriptions per day. Furthermore, the pharmacy is currently licensed in 14 states, with plans to expand nationwide to enhance service delivery capabilities. The recent expansion into advanced non-sterile compounding, operating under the FDA's 503A designation, allows for tailored therapies and improved fulfillment economics compared to third-party partners.

The push toward payers and employers represents the potential B2B channels for employers and private payers. Management has signaled this as a key area for 2026 growth, specifically mentioning insurance enablement. The company stated they are 100% ready to go with Medicare once coverage is secured. Turning on insurance coverage has a measurable impact on acquisition costs, as it has been shown to reduce customer acquisition costs by over a third.

Here's a quick look at some key channel performance metrics from Q3 2025:

Channel Metric	Value (Q3 2025)	Context/Detail
Active Telehealth Subscribers	~310,000	Represents a 14% year-over-year increase.
Telehealth Revenue	$47.3 million	Grew 18% year-over-year.
Pharmacy Licensing Footprint	14 states	Plans for nationwide expansion.
Branded GLP-1 Cash Price (Wegovy/Ozempic)	$199 per month	For the first two fills (0.25 mg and 0.5 mg doses).
Advertising Spend as % of Revenue	48%	Year-to-date 2025 figure, down from 70% in 2021.

The company is clearly focused on driving volume through its DTC digital channels while simultaneously de-risking the model by integrating pharmacy and preparing for payer reimbursement. If onboarding takes 14+ days, churn risk rises, so the pharmacy integration is defintely key to maintaining the patient experience.

Finance: draft 13-week cash view by Friday.

LifeMD, Inc. (LFMD) - Canvas Business Model: Customer Segments

You're looking at the core patient base LifeMD, Inc. is serving as of late 2025, which is heavily weighted toward virtual, chronic care management.

The platform supports a broad base, with over 310,000 active telehealth subscribers as of September 30, 2025. This base has generated 1.3 million virtual consults conducted through the third quarter of 2025.

The customer base is segmented by need and condition:

• Cash-pay patients seeking affordable, convenient access to specialty medications.
• Individuals with chronic conditions like obesity, hair loss, and hormone imbalances.
• Men seeking health and wellness treatments (RexMD).
• Women seeking hormone, dermatology, and behavioral health services.
• Patients in all 50 states seeking virtual primary care.

The segment seeking affordable, convenient access includes patients who can see an affiliated provider for as little as $39/mo for routine, preventive care via their PC or smartphone. LifeMD, Inc. is also offering market-leading pricing for GLP-1 medications to self-pay patients.

For chronic conditions, LifeMD, Inc. offers specialized treatment across more than 200 conditions. The weight management program, which had over 75,000 patient subscribers as of December 31, 2024, is a core focus for chronic care.

The men's health vertical, RexMD, is showing traction, having returned to growth by adding approximately 10,000 net new subscribers.

The expansion into women's health and behavioral health is viewed as a major growth driver, with management labeling both as having the potential to each become 9-figure businesses over the next 3 years.

For virtual primary care, LifeMD, Inc. maintains a 50-state affiliated medical group, though they were projecting licensing in 35 states within 60-90 days as of November 17, 2025. The company's affiliated pharmacy was licensed in 49 states as of the first quarter of 2025.

Here is a breakdown of key operational metrics related to patient reach:

Metric	Value as of Late 2025	Source Context
Active Telehealth Subscribers	Over 310,000	Q3 2025 End
Total Virtual Consults Conducted	1.3 million	As of September 30, 2025
RexMD Net New Subscribers Added	Approximately 10,000	Recent Growth Period
Weight Management Subscribers	Over 75,000	As of December 31, 2024
Affiliated Medical Group Reach	50-state	Platform Capability

If onboarding takes 14+ days, churn risk rises.

Finance: draft 13-week cash view by Friday.

LifeMD, Inc. (LFMD) - Canvas Business Model: Cost Structure

You're looking at the cost side of LifeMD, Inc.'s (LFMD) operations as of late 2025, post-WorkSimpli divestiture, focusing on the core telehealth and pharmacy platform.

High customer acquisition costs (CAC) from digital marketing spend.

Concerns over rising customer acquisition costs were a factor in the period leading up to the Q3 2025 earnings report, specifically noted in relation to the RexMD segment and the sale of obesity drugs like Wegovy and Zepbound. To be fair, the company stated that turning on insurance coverage reduced customer acquisition costs by over a third. In Q2 2025, the RexMD business saw temporarily elevated CAC in the ED market, though early Q3 data suggested a return to healthier levels.

Costs of goods sold (COGS) for prescription and compounded medications.

The cost of fulfilling services directly impacts the gross margin. For the core telehealth segment in Q3 2025, the gross margin stood at 86%. This implies that the Cost of Goods Sold (COGS) for telehealth revenue, which was $47.3 million in Q3 2025, represented approximately 14% of that segment's revenue. Management noted that the overall consolidated gross margin for Q3 2025 was 88%.

Compensation for the affiliated medical group and patient care staff.

The operational cost tied to clinical services is substantial, supporting the platform's scale. LifeMD's affiliated medical group has completed 1.2 million virtual consultations. The cost of telehealth revenue, which includes physician consult fees, surged 66% year-to-date (YTD) leading up to Q3 2025, outpacing revenue growth for that period.

Technology platform maintenance and development expenses.

A significant capital outlay is directed toward vertical integration to control fulfillment costs. LifeMD, Inc. spent $10.2 million year-to-date (YTD) in 2025 to develop a wholly-owned affiliated commercial pharmacy with compounding capabilities. This move is intended to internalize fulfillment and manage the rising costs associated with medication fulfillment.

General and administrative costs, including litigation and compliance.

General and administrative expenses cover the overhead of running the enterprise. For the full fiscal year ending December 31, 2024, LifeMD, Inc. reported total Operating Expenses of $228.60M. More recently, the company recorded Restructuring Costs of $10.9Mn for the quarter ending June 2025. Furthermore, past G&A included litigation costs related to matters like the William Blair LLC case and the Harborside Advisors agreement in 2023.

Here's a quick look at the key cost-related metrics from the latest available data:

Cost Component/Metric	Value/Rate	Period/Context
Telehealth Gross Margin	86%	Q3 2025
Consolidated Gross Margin	88%	Q3 2025
Telehealth Revenue (Q3)	$47.3 million	Q3 2025
Compounding Pharmacy Investment (YTD)	$10.2 million	YTD 2025
Total Operating Expenses	$228.60M	Fiscal Year Ended 2024-12-31
Restructuring Costs (Quarterly)	$10.9Mn	June 2025
Virtual Consultations Completed	1.2 million	To date

The company's focus on vertical integration, like the new compounding pharmacy investment, is a direct response to controlling the variable costs associated with prescriptions. Also, the impact of insurance on CAC is a major lever for managing marketing spend efficiency.

• Insurance activation reduces CAC by over a third.
• Telehealth revenue growth was 18% year-over-year in Q3 2025.
• The cost of telehealth revenue surged 66% YTD leading up to Q3 2025.
• Active telehealth subscribers reached approximately 310,000 in Q3 2025.

Finance: draft 13-week cash view by Friday.

LifeMD, Inc. (LFMD) - Canvas Business Model: Revenue Streams

You're looking at the core ways LifeMD, Inc. brings in money as of late 2025. It's centered on recurring subscription revenue and product sales.

The primary driver is the recurring revenue from the telehealth platform, which supports the direct sales components of the business model.

Revenue Streams include:

• Telehealth subscription and membership fees from over 310,000 subscribers.
• Direct sales of prescription medications and compounded products.
• Sales of nutritional supplements and over-the-counter (OTC) products.

Here's the quick math on the most recent reported figures and the full-year outlook:

Revenue Component	Period/Scope	Amount
Full-Year 2025 Revenue Projection	Fiscal Year 2025 Guidance	$192 million to $193 million
Telehealth Segment Revenue	Q3 2025	$47.3 million
Total Consolidated Revenue	Q3 2025	$60.2 million
Non-Telehealth Revenue (Implied)	Q3 2025	$12.9 million

The active subscriber base provides the foundation for these revenue streams. As of the end of Q3 2025, the count stood at:

• Active Telehealth Subscribers: Approximately 310,000
• Year-over-Year Subscriber Growth: 14%

The telehealth revenue stream itself is a significant portion of the total top line, as seen in the quarterly breakdown:

• Telehealth Revenue Contribution (Q3 2025): $47.3 million
• Total Revenue (Q3 2025): $60.2 million